Prostate Cancer Diagnosis and Management During One Year of the COVID-19 Pandemic.
Anticancer Res
; 41(6): 3127-3130, 2021 Jun.
Article
in English
| MEDLINE | ID: covidwho-1259822
ABSTRACT
BACKGROUND/AIM:
To evaluate the diagnosis and treatment of prostate cancer (PCa) during 1 year of the COVID-19 pandemic. PATIENTS ANDMETHODS:
The management of men with PCa during COVID-19 pandemic (March 2020-2021) was compared with the clinical activity of the 12 months before the COVID-19 pandemic (March 2019-2020).RESULTS:
The number of clinical visits, prostate biopsy, and men enrolled in active surveillance was significantly lower during the COVID-19 pandemic (p<0.05); on the contrary, the number of cases with advanced (pT3b 11.2 vs. 25.6%; nodal positive 14.8 vs. 46.1%) and metastatic (5.9 vs. 9.3%) PCa increased. The number of open radical prostatectomies increased compared with the ones using a laparoscopic approach; moreover, more men were treated with external radiotherapy (25.1 vs. 54.2%).CONCLUSION:
The guideline recommendations in the management of PCa should constantly adapt to the epidemiological evolution, but the overall cost of delayed diagnosis will increase in the near future.Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Prostatic Neoplasms
/
Pandemics
/
COVID-19
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Limits:
Humans
/
Male
Language:
English
Journal:
Anticancer Res
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS